Compare Stocks: IVA, CPRX, GPCR, and OGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$31.49	$31.45	$19.05 ▼ $32.56	$3.86B	0.74	2.62 million shs	N/A
GPCR Structure Therapeutics	$54.51 -0.3%	$49.22	$18.26 ▼ $94.90	$3.87B	-1.43	557,946 shs	555,883 shs
IVA Inventiva	$4.60	$4.19	$3.35 ▼ $7.98	$955.45M	0.7	730,654 shs	573,821 shs
OGN Organon & Co.	$13.72 0.0%	$13.52	$5.69 ▼ $13.72	$3.60B	1.55	2.63 million shs	2.11 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	0.00%	0.00%	+0.99%	+55.97%
GPCR Structure Therapeutics	0.00%	+2.58%	+18.42%	+40.89%	+184.50%
IVA Inventiva	0.00%	-4.17%	+1.77%	-15.44%	+14.43%
OGN Organon & Co.	0.00%	+0.88%	+1.55%	+2.39%	+46.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$31.49	$31.45	$19.05 ▼ $32.56	$3.86B	0.74	2.62 million shs	N/A
GPCR Structure Therapeutics	$54.51 -0.3%	$49.22	$18.26 ▼ $94.90	$3.87B	-1.43	557,946 shs	555,883 shs
IVA Inventiva	$4.60	$4.19	$3.35 ▼ $7.98	$955.45M	0.7	730,654 shs	573,821 shs
OGN Organon & Co.	$13.72 0.0%	$13.52	$5.69 ▼ $13.72	$3.60B	1.55	2.63 million shs	2.11 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	0.00%	0.00%	+0.99%	+55.97%
GPCR Structure Therapeutics	0.00%	+2.58%	+18.42%	+40.89%	+184.50%
IVA Inventiva	0.00%	-4.17%	+1.77%	-15.44%	+14.43%
OGN Organon & Co.	0.00%	+0.88%	+1.55%	+2.39%	+46.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	2.56	Moderate Buy	$32.00	1.62% Upside
GPCR Structure Therapeutics	2.89	Moderate Buy	$110.91	103.47% Upside
IVA Inventiva	3.09	Buy	$16.56	259.90% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-16.88% Downside

Current Analyst Ratings Breakdown

Latest IVA, CPRX, GPCR, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	GPCR Structure Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $97.00
8/7/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$113.00 ➝ $110.00
8/3/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/17/2026	GPCR Structure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IVA Inventiva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IVA Inventiva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
7/13/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
6/11/2026	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $70.00
6/3/2026	CPRX Catalyst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$596.96M	6.46	$2.92 per share	10.77	$7.76 per share	4.06
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$19.06 per share	N/A
IVA Inventiva	$5.07M	188.45	N/A	N/A	($0.22) per share	-20.91
OGN Organon & Co.	$6.22B	0.58	$5.79 per share	2.37	$3.83 per share	3.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$214.33M	$1.74	18.10	10.22	0.96	37.08%	35.76%	31.31%	N/A
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	N/A
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.81	3.99	1.27	3.41%	88.97%	6.03%	N/A

Latest IVA, CPRX, GPCR, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A

Latest IVA, CPRX, GPCR, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	7.10	6.84
GPCR Structure Therapeutics	N/A	20.75	26.16
IVA Inventiva	N/A	3.16	3.16
OGN Organon & Co.	8.43	1.95	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
GPCR Structure Therapeutics	91.78%
IVA Inventiva	19.06%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
GPCR Structure Therapeutics	5.50%
IVA Inventiva	32.00%
OGN Organon & Co.	1.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.42 million	109.69 million	Optionable
GPCR Structure Therapeutics	136	71.08 million	67.17 million	Optionable
IVA Inventiva	100	207.71 million	141.24 million	Not Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable

IVA, CPRX, GPCR, and OGN Headlines

Recent News About These Companies

Quantinno Capital Management LP Sells 98,466 Shares of Organon & Co. $OGN

August 13 at 4:40 AM | marketbeat.com

Sei Investments Co. Has $1.14 Million Holdings in Organon & Co. $OGN

August 13 at 4:39 AM | marketbeat.com

Organon & Co. (NYSE:OGN) Reaches New 1-Year High - Should You Buy?

August 13 at 4:39 AM | marketbeat.com

Organon & Co. (OGN)

August 13 at 2:46 AM | sg.finance.yahoo.com

Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System

August 12, 2026 | marketbeat.com

Rep. Kevin Hern Sells Shares of Organon & Co. (NYSE:OGN)

August 12, 2026 | marketbeat.com

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

August 11, 2026 | businesswire.com

Organon & Co. (NYSE:OGN) Reaches New 52-Week High - Should You Buy?

August 7, 2026 | marketbeat.com

Organon & Co. $OGN Shares Sold by Dimensional Fund Advisors LP

August 7, 2026 | marketbeat.com

Organon & Co. (NYSE:OGN) to Issue $0.02 Quarterly Dividend

July 31, 2026 | marketbeat.com

Organon & Co. (NYSE:OGN) Issues Earnings Results, Misses Expectations By $0.02 EPS

July 31, 2026 | marketbeat.com

Organon: Q2 Earnings Snapshot

July 31, 2026 | stamfordadvocate.comS

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

July 31, 2026 | zacks.com

Organon (OGN) Lags Q2 Earnings Estimates

July 31, 2026 | zacks.com

Organon Announces Quarterly Dividend

July 31, 2026 | businesswire.com

Organon Reports Q2 Results Amid Pending Sun Pharma Merger

July 31, 2026 | tipranks.com

Orographic Financial Advisors LLC Acquires New Holdings in Organon & Co. $OGN

July 31, 2026 | marketbeat.com

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages

July 30, 2026 | marketbeat.com

First Trust Advisors LP Has $19.33 Million Position in Organon & Co. $OGN

July 30, 2026 | marketbeat.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

July 28, 2026 | zacks.com

Organon & Co. (OGN) to Announce Quarterly Earnings on Tuesday

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IVA, CPRX, GPCR, and OGN Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$31.49 0.00 (0.00%)

As of 07/16/2026

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Structure Therapeutics NASDAQ:GPCR

$54.51 -0.19 (-0.35%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$53.55 -0.96 (-1.76%)

As of 08/14/2026 07:57 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Inventiva NASDAQ:IVA

$4.60 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.60 0.00 (-0.11%)

As of 08/14/2026 04:10 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Organon & Co. NYSE:OGN

$13.72 -0.01 (-0.04%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$13.72 +0.01 (+0.04%)

As of 08/14/2026 07:40 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVA, CPRX, GPCR, and OGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVA, CPRX, GPCR, and OGN Earnings

Compare Dividends

Latest IVA, CPRX, GPCR, and OGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVA, CPRX, GPCR, and OGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVA, CPRX, GPCR, and OGN Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

Structure Therapeutics NASDAQ:GPCR

Inventiva NASDAQ:IVA

Organon & Co. NYSE:OGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools